» Articles » PMID: 39179754

CircXPO6 Promotes Breast Cancer Progression Through Competitively Inhibiting the Ubiquitination Degradation of C-Myc

Overview
Publisher Springer
Specialty Biochemistry
Date 2024 Aug 23
PMID 39179754
Authors
Affiliations
Soon will be listed here.
Abstract

The number of breast cancer (BC) patients is increasing year by year, which is severely endangering to human life and health. c-Myc is a transcription factor, studies have shown that it is a very significant factor in tumor progression, but how it is regulated in BC is still not well understood. Here, we used the RIP microarray sequencing to confirm circXPO6, which had a high affinity with c-Myc and highly expressed in triple-negative breast cancer (TNBC) tissues and cells. CircXPO6 overexpression promoted tumor growth in vivo and in vitro. Furthermore, circXPO6 largely promoted the expression of genes related to glucose metabolism, such as GLUT1, HK2, and MCT4 in TNBC cells. Finally, high levels of circXPO6 expression were found to be closely associated with malignant pathological factors, such as tumor size, lymph node metastasis, TNM staging, and histopathological grading of TNBC. Mechanistically, circXPO6 interacted with c-Myc to prevent speckle-type POZ-mediated c-Myc ubiquitination and degradation, thus promoting TNBC progression. Through the regulation of c-Myc-mediated signal transduction, circXPO6 plays a key role in TNBC progresses. This discovery can provide new ideas for TNBC molecular targeted therapy.

References
1.
Siegel R, Miller K, Fuchs H, Jemal A . Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1):7-33. DOI: 10.3322/caac.21654. View

2.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

3.
Tang Y, Tian W, Zheng S, Zou Y, Xie J, Zhang J . Dissection of FOXO1-Induced LYPLAL1-DT Impeding Triple-Negative Breast Cancer Progression via Mediating hnRNPK/β-Catenin Complex. Research (Wash D C). 2023; 6:0289. PMC: 10726293. DOI: 10.34133/research.0289. View

4.
Ensenyat-Mendez M, Llinas-Arias P, Orozco J, Iniguez-Munoz S, Salomon M, Sese B . Current Triple-Negative Breast Cancer Subtypes: Dissecting the Most Aggressive Form of Breast Cancer. Front Oncol. 2021; 11:681476. PMC: 8242253. DOI: 10.3389/fonc.2021.681476. View

5.
Asleh K, Riaz N, Nielsen T . Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications. J Exp Clin Cancer Res. 2022; 41(1):265. PMC: 9434975. DOI: 10.1186/s13046-022-02476-1. View